Pluri Inc. Logo

Pluri Inc.

Develops cell therapies from placental cells for inflammatory & hematologic disorders.

PLUR | US

Overview

Corporate Details

ISIN(s):
US72940R3003
LEI:
Country:
United States of America
Address:
MATAM ADVANCED TECHNOLOGY PARK, 0 HAIFA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company specializing in the research, development, and manufacturing of cell-based products and therapeutics. The company leverages proprietary 3D cell-expansion technology platforms to create solutions from human placental cells. Pluri aims to improve human well-being and sustainability by developing therapies for various conditions, including ischemic, inflammatory, and hematologic disorders. It collaborates with research partners and academic institutions to advance its cell-based product pipeline for commercial use.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pluri Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea 206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France EAPI
Eurobio Scientific Logo
Develops & distributes specialty IVD tests for oncology, transplant & infectious diseases.
France ALERS
European Institute of Science AB Logo
Manufactures diagnostic assays and point-of-care instruments for the veterinary health market.
Sweden EURI B
Evoke Pharma Inc Logo
Develops and commercializes a nasal spray for diabetic gastroparesis symptom relief.
United States of America EVOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.